MCRB today
$1.38-$0.12 (-8.00%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $2.78
Key levels
Resistance$2.26
Resistance$1.68
Latest news & SEC filings
EarningsSeres Therapeutics reports Q3 2026 earnings, updates SER-155 plans
EarningsSeres Therapeutics Posts Wider-Than-Expected Quarterly Loss, Revenue Falls Short
SEC FilingSeres Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All MCRB news →About Seres Therapeutics
Seres Therapeutics is a clinical-stage biopharmaceutical company developing oral live biotherapeutic products, which are defined bacterial consortia intended to modulate disease-related pathways in the body. Its pipeline includes SER-155, under study in stem cell transplant recipients and in colitis linked to immune checkpoint inhibitors, SER-603 for inflammatory bowel conditions, and SER-147 for bloodstream and peritoneal infections in people whose livers are failing. The company focuses on medically vulnerable populations, such as transplant recipients, cancer patients, and those with chronic liver conditions, and operates in the United States.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Seres Therapeutics, Inc. (MCRB)
What Is the Price Target for MCRB?
SEPT Low Target
$12.00
SEPT Mid Target
$12.00
SEPT High Target
$12.00
Analyst Consensus
$12.00
Is MCRB a Buy or Sell Right Now?
Thesis
- •Revenue growing -88.9% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MCRB.
Start Free Trial →Is MCRB Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$11.31
21
Moat Score
NONE
6/9
Piotroski Score
-11.7
Altman Z-Score
What Is Smart Money Doing with MCRB?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Shaff Eric D. | director | Sale | 259 | $2K | May 18, 2026 |
| Brady Kelly | officer | Sale | 59 | $444.27 | May 18, 2026 |
| DesRosier Thomas | officer | Sale | 79 | $594.87 | May 18, 2026 |
| Henn Matthew R | officer | Sale | 77 | $579.81 | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MCRB Growth Story
Revenue YoY
-88.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
100.6%
Revenue Trend
ACCELERATING
Dark Pool Trades for MCRB
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MCRB, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:52:01 | $1.40 | 2,700 | $$4K | BUY |
| 14:38:37 | $1.30 | 4,307 | $$6K | SELL |
| 14:33:48 | $1.47 | 2,410 | $$4K | SELL |
| 21:26:56 | $1.50 | 3,318 | $$5K | BUY |
| 20:59:28 | $1.51 | 5,000 | $$8K | BUY |
5 dark pool trades shown · $$25K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Seres Therapeutics, Inc. (MCRB) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MCRB — frequently asked questions
What is MCRB stock price today?
Seres Therapeutics, Inc. (MCRB) is at $1.38, down 8.00% (-$0.12) at the Nov 12, 2026 close.
Why is MCRB stock moving today?
Latest MCRB news — Nov 5, 2026: Seres Therapeutics reports Q3 2026 earnings, updates SER-155 plans · Nov 4, 2026: Seres Therapeutics Posts Wider-Than-Expected Quarterly Loss, Revenue Falls Short
What is the MCRB price target?
The average analyst price target for MCRB is $12.00, ranging from $12 to $12, based on 1 analysts. Latest: HC Wainwright & Co. initiates on Jun 23, 2026.
What do analysts rate MCRB?
Analyst ratings for MCRB: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did MCRB beat earnings?
MCRB last reported on Nov 4, 2026: EPS -$1.06 vs -$1.00 expected — a miss of 5.5%.
Does MCRB pay a dividend?
MCRB does not currently pay a dividend.
What are MCRB support and resistance levels?
Resistance: $1.68, $2.26, $2.78.
What are insiders doing with MCRB?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on MCRB?
Nov 5, 2026: Seres Therapeutics reports Q3 2026 earnings, updates SER-155 plans · Nov 4, 2026: Seres Therapeutics Posts Wider-Than-Expected Quarterly Loss, Revenue Falls Short · Nov 4, 2026: Seres Therapeutics, Inc. filed a report on a major company event (Form 8-K)